Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2020-01-08 Legal Proceedings Report
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science annonce que la FDA autorise le recrutement de patients aux USA dans l’étude de phase 3 du masitinib dans le traitement du cancer de la prostate hormono-resistant éligible à la chimiothérapi
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 8, 2020, announcing that the US FDA has authorized the initiation of patient recruitment for a Phase 3 clinical trial (AB12003) for masitinib in treating prostate cancer. It details the study design, endpoints (PFS), patient population, interim analysis results, and provides background information on the disease and the drug. This type of announcement, focusing on clinical trial progress, regulatory milestones (FDA IND authorization), and future result timelines, is characteristic of an Earnings Release (ER) or a general corporate/investor update. Since it is a specific announcement of a key operational/clinical event rather than a full financial report (10-K, IR) or a transcript (CT), and it is not a formal notice of dividend (DIV) or management change (MANG), the most fitting category is Earnings Release (ER), as these often contain operational highlights alongside financial context, or it could be classified as a Regulatory Filing (RNS) if it were less specific. Given the detailed nature of the clinical update and the explicit mention of results being available by year-end 2020, it functions as a significant operational update often bundled with earnings communications. However, looking strictly at the definitions, it is a specific announcement about a clinical trial milestone. Since there is no specific category for 'Clinical Trial Update', and it is not a formal financial report, it falls best under the general 'Regulatory Filings' (RNS) as a significant corporate announcement, or potentially 'ER' if it were tied to a quarterly report cycle. Given the content is purely operational/clinical news, RNS is the safest general regulatory announcement category, though ER is plausible if this was released near an earnings date. I will lean towards RNS as the primary category for non-standard, significant corporate news that isn't a defined financial report or management change.
2020-01-08 French
AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
Regulatory Filings Classification · 1% confidence The document is a press release dated January 08, 2020, announcing that the FDA has cleared the IND application for a Phase 3 study (AB12003) involving the drug masitinib for metastatic castrate-resistant prostate cancer (mCRPC). It details the study design, patient population, interim analysis results, and provides an expected timeline for topline results (end of 2020). This content is characteristic of an announcement regarding clinical trial progress and regulatory milestones, which is typically classified as an Investor Presentation (IP) if it's a detailed deck, or more generally, a Regulatory Filing (RNS) or an Earnings Release (ER) if it contains key operational updates. Since it is a formal announcement of a significant regulatory clearance (IND clearance) and clinical trial update, and does not appear to be a full financial report (10-K, IR) or a transcript (CT), it fits best under the general category for significant corporate/regulatory news that isn't strictly financial results or management changes. Given the focus on regulatory clearance (IND) and clinical trial progress, it is a key piece of investor information. However, it is not a standard Earnings Release (ER) which focuses on financial figures. It is a specific announcement of a regulatory/clinical event. In the absence of a specific 'Clinical Trial Update' code, this type of press release announcing regulatory milestones and trial progress often falls under the broad 'Regulatory Filings' (RNS) or sometimes an 'Investor Presentation' (IP) if it were structured as a deck. Since it is a formal press release detailing operational/regulatory progress, RNS is the most appropriate general regulatory fallback, although it contains elements of an Investor Presentation's content focus. Given the nature of the announcement (FDA clearance, trial details), it is a significant piece of non-financial, operational news. I will classify it as RNS as it is a general regulatory announcement not covered by other specific codes like DIV, DIRS, or ER.
2020-01-08 English
AB Science annonce la publication de nouveaux résultats dans la revue Glia renforçant la plausibilité du mode d’action du masitinib dans la Sclérose Latérale Amyotrophique
Regulatory Filings Classification · 1% confidence The document is a press release dated December 23, 2019, from AB Science SA, announcing the publication of new scientific results in the journal *Glia* regarding the mechanism of action of masitinib in Amyotrophic Lateral Sclerosis (ALS). It details scientific findings, quotes researchers, provides context about the drug (masitinib), and includes standard company information and forward-looking statements. This type of announcement, focusing on scientific progress, clinical trial updates, or key research findings, is typically classified as an Investor Presentation (IP) if it were a formal deck, or often falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if it were tied to quarterly results. However, since it is a specific announcement about scientific data supporting a drug's potential, and it is not a formal financial report (10-K, IR, ER), nor a management discussion (MDA), nor a proxy/dividend notice, it best fits the general category for significant, non-standard corporate news that is disseminated to investors. Given the options, and since it is a detailed update on a key asset's scientific rationale, it is most closely aligned with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a press release format detailing scientific rationale rather than a formal presentation deck, RNS is the most appropriate fallback for significant, non-standard corporate news dissemination, although IP is also plausible if the content were structured as a presentation. Given the structure (press release format announcing research publication), RNS is the safest classification for a general regulatory/corporate update that isn't a core financial report.
2019-12-23 French
AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
Regulatory Filings Classification · 1% confidence The document is a press release dated December 23, 2019, announcing the publication of new scientific results in the peer-reviewed journal *Glia* that support the potential mode of action of the drug masitinib in ALS. It details scientific findings, quotes researchers, and includes sections about the drug and the company (AB Science). This type of announcement, which communicates significant scientific or operational updates outside of mandatory financial reporting cycles (like 10-K or ER), is best classified as a general Regulatory Filing or Announcement, as it does not fit the specific definitions for Earnings Release (ER), Interim Report (IR), or a formal Audit Report (AR). Since it is a specific announcement about scientific progress rather than a general regulatory filing fallback (RNS), and it is not a presentation (IP) or a management discussion (MDA), the most appropriate category among the provided options for a significant, non-financial, non-meeting-related corporate update is the general Regulatory Filing (RNS), although it strongly resembles an Investor Presentation (IP) in structure, it is explicitly reporting on a scientific publication, making RNS the safer general category if a more specific one like 'Research Update' is unavailable. Given the options, RNS serves as the best fit for a non-standard, material corporate announcement.
2019-12-23 English
AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
Environmental & Social Information Classification · 1% confidence The document is an announcement from AB Science dated December 9, 2019, stating that three scientific abstracts regarding their compound AB8939 were published in the special ASH Annual Meeting issue of the journal 'Blood'. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It is an announcement detailing the publication of scientific data/research findings, which often accompanies investor relations activities or scientific updates. Since the core content is about the publication of scientific abstracts and preclinical data supporting a drug candidate, it aligns best with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given that it is a press release announcing the publication of scientific data intended for investors and the scientific community, 'Investor Presentation' (IP) is a strong fit, as these announcements often serve as key updates on R&D progress. However, since it is specifically announcing the publication of abstracts in a journal, and not a formal presentation deck, it is a specific type of scientific/regulatory update. Comparing the options, it is a specific announcement about research findings, which is often disseminated via press release. It is not a formal financial report, dividend notice, or management change. It is closest to an Investor Presentation (IP) in terms of content focus (drug development updates), but since it is a press release announcing external publication, 'Regulatory Filings' (RNS) serves as a broad category for such non-standard announcements. Given the context of scientific data release, and the lack of a specific 'Scientific Update' code, RNS is the most appropriate fallback for a press release detailing research publication, although IP is conceptually close. I will classify it as RNS as it is a general regulatory/corporate announcement about a publication.
2019-12-09 English
AB Science annonce la publication de trois résumés d’étude de la molécule AB8939 dans l’édition spéciale de la revue Blood consacré au congrès annuel de 'ASH
Regulatory Filings Classification · 1% confidence The document is a press release dated December 9, 2019, announcing that AB Science has published three study abstracts for its molecule AB8939 in a special edition of the journal *Blood* ahead of the American Society of Hematology (ASH) annual congress. The text details preclinical findings and mentions that the full abstracts are accessible on the *Blood* journal website. This structure—announcing the publication of research findings, often referencing a conference or journal release—is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more specifically, a general announcement about scientific data dissemination. Since the core content is the announcement of scientific data publication (not the financial results themselves, nor a formal regulatory filing like 10-K or IR), and it is a formal communication to the market, it fits best under the general category for regulatory/corporate announcements that aren't strictly financial reports or specific corporate actions. Given the options, this is a scientific/research update announcement. While it is not a formal Earnings Release (ER), it is an announcement of key company developments (research data). However, looking closely at the definitions, it is not a formal financial report (10-K, IR), nor a management change (MANG), nor a dividend notice (DIV). It is an announcement about research data being presented/published. This type of announcement, detailing scientific progress and publication, often falls under general corporate news. Since there isn't a specific 'Research Update' code, we must choose the closest fit. It is not a Call Transcript (CT), Investor Presentation (IP), or Fund Factsheet (FS). It is a press release announcing data that will be presented at a major medical conference. This is a significant corporate event announcement. Given the available codes, 'Regulatory Filings' (RNS) is the broadest category for non-standard announcements, but 'Earnings Release' (ER) is often used loosely for major period announcements, though this is research, not earnings. Since the document is a formal press release announcing the publication of scientific abstracts, and it is not a formal financial report, the most appropriate general category for significant, non-listed corporate news is RNS, or potentially ER if the company treats major scientific milestones as equivalent to periodic results announcements. Given the focus is purely scientific data publication, RNS (Regulatory Filings/General Announcement) is the safest fallback, although it is a very specific type of announcement. If we consider the context of a pharmaceutical company, the release of study data is a critical corporate event. Since it is not a formal financial report, and it is not a proxy statement (PSI) or management report (MDA), RNS serves as the best catch-all for significant, non-categorized corporate news releases.
2019-12-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.